Sean Davies

Associate Professor

Vanderbilt University

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Sean Davies is an Associate Professor at Vanderbilt University in the United States. His research focuses on lipid metabolism and cardiovascular health, particularly the role of oxidative modifications in high-density lipoprotein (HDL) function and the implications for atherosclerosis and autoimmune diseases. Recent articles from his work explore the therapeutic potential of targeting reactive dicarbonyls and the engineering of gut microbiota to manage chronic conditions.

Articles (10)

Year:

2025

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Year:

2020

Year:

2020

Collaborators (7)

Jaya Krishnan

Vanderbilt University Medical Center

UNITED STATES

View details

Wei Chen

Research Associate Professor

Vanderbilt University Medical Center

UNITED STATES

View details

Patricia Yancey

Research Assistant Professor

Vanderbilt University Medical Center

UNITED STATES

View details

Leslie Crofford

Vanderbilt University Medical Center

UNITED STATES

View details

Amanda C. Doran

Vanderbilt University Medical Center

UNITED STATES

View details

Justin Van Beusecum

Assistant Professor of Medicine

Medical University of South Carolina

UNITED STATES

View details

Sergey Dikalov

Vanderbilt University Medical Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Sean Davies

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

N-aldehyde-modified phosphatidylethanolamines generated by lipid peroxidation are robust substrates of N-acyl phosphatidylethanolamine phospholipase D

HDL Function and Atherosclerosis: Reactive Dicarbonyls as Promising Targets of Therapy

Isolevuglandins disrupt PU.1-mediated C1q expression and promote autoimmunity and hypertension in systemic lupus erythematosus.

Selective measurement of NAPE-PLD activity via a PLA1/2-resistant fluorogenic N-acyl-phosphatidylethanolamine analog

Oxidative modification of HDL by lipid aldehydes impacts HDL function

Myeloperoxidase-induced modification of HDL by isolevuglandins inhibits paraoxonase-1 activity

Isolevuglandins as mediators of disease and the development of dicarbonyl scavengers as pharmaceutical interventions

Progressively decreasing plasma high-density lipoprotein cholesterol levels preceding diagnosis of smoldering myeloma

Symmetrically substituted dichlorophenes inhibit N-acyl-phosphatidylethanolamine phospholipase D

Engineering the gut microbiota to treat chronic diseases

Collaborators (7)

Jaya Krishnan

Wei Chen

Patricia Yancey

Leslie Crofford

Amanda C. Doran

Justin Van Beusecum

Sergey Dikalov

Make your next move.